Pancreatic cancer is the 12th most common cancer worldwide but has the sixth-highest death rate. Early detection is crucial because survival drops sharply with disease progression: localized cancer has a 44% five-year survival rate, compared with 16% for regional disease and only 3% for distant disease. Unfortunately, fewer than one in seven cases are diagnosed early. The disease typically develops slowly from precursors such as pancreatic intraepithelial neoplasia or cystic lesions, providing a long window for potential detection.
Screening is not recommended for the general population, but high-risk individuals should be monitored. This includes people with certain genetic mutations—like BRCA1/2, PALB2, ATM, CDKN2A, PRSS1, or STK11—or those with a strong family history of pancreatic cancer. Screening usually begins between ages 35 and 50 depending on specific risk factors. Annual imaging with MRI/MRCP or endoscopic ultrasound is used, with EUS better for detecting solid lesions and MRI/MRCP more effective for cystic changes.
Screening in high-risk individuals has been shown to improve outcomes, with more cancers detected at early stages and significantly better survival rates. While there is some risk of unnecessary surgery for benign lesions, complications are generally low. Research is advancing in AI-assisted imaging and blood-based biomarkers, including protein panels, circulating tumor DNA, and miRNAs, which may further improve early detection and risk assessment in the future.